Q-omics provides the consensus-scored CORT profile across patient tissues and cancer cell-line models. CORT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CORT is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, CORT RNA expression shows 18,537 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where CORT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CORT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CORT survival associations across molecular data types. CORT RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CORT RNA expression–survival associations across cancer types. High CORT expression shows unfavorable associations in ACC, KIRC, KICH and LIHC, but favorable associations in PAAD and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CORT RNA expression.
This table summarizes CORT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CORT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CORT shows lower tumor expression in KICH and BRCA and higher tumor expression in BLCA, LUSC, HNSC and LIHC. The BLCA box plot shows higher CORT RNA expression in tumor versus normal tissue (log2 FC = +0.474, t-test p < 0.001).
This table shows molecular features associated with CORT in patient tissues and cancer cell lines. In patient samples, CORT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CORT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
